Generex Biotechnology (GNBTQ) 10-Q 16 Dec 19 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Oct. 31, 2019	Dec. 13, 2019
Document And Entity Information
Entity Registrant Name	GENEREX BIOTECHNOLOGY CORP
Entity Central Index Key	0001059784
Current Fiscal Year End Date	--07-31
Entity Filer Category	Non-accelerated Filer
Entity's Reporting Status Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-29169
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 31, 2019
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		47,685,513

UNAUDITED CONDENSED INTERIM CON

UNAUDITED CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Current Assets
Cash and cash equivalents	$ 540,254	$ 298,485
Accounts receivable, net	154,575	36,311
Inventory, net	727,263	363,008
Other current assets	451,344	275,731
Total Current Assets	1,873,436	973,535
Property and equipment	531,888	499,993
Goodwill	38,901,126	38,297,573
Intangible assets	10,802,442	9,834,269
Operating lease right-of-use assets - net	97,553	0
Other assets, net	33,804	30,621
TOTAL ASSETS	52,240,249	49,635,991
Current Liabilities
Accounts payable and accrued expenses	22,447,533	19,055,822
Notes payable, current	10,163,610	8,368,379
Loans from related parties	72,612	19,700
Operating lease liabilities - current	75,892	0
Deferred tax liability	1,502,122	1,502,122
Total Current Liabilities	34,261,769	28,946,023
Derivative liability	8,797,354	7,820,283
Common stock payable	215,793	1,123,188
Operating lease liabilities - net of current portion	22,048	0
Total Liabilities	43,296,964	37,889,494
Redeemable non-controlling interest	4,073,898	4,073,898
Stockholders' equity
Common stock, $0.001 par value; authorized 750,000,000 shares; 44,336,023 and 62,290,940 issued and outstanding at October 31, 2019 and July 31, 2019, respectively	44,335	62,290
Additional paid-in capital	417,081,503	408,566,529
Accumulated deficit	(427,853,820)	(418,727,875)
Accumulated other comprehensive income	796,922	797,216
Non-controlling interest	14,800,447	16,974,439
Total Stockholders' Equity	4,869,387	7,672,599
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 52,240,249	$ 49,635,991

UNAUDITED CONDENSED INTERIM C_2

UNAUDITED CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 31, 2019	Jul. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	44,336,023	62,290,940
Common stock, shares outstanding	44,336,023	62,290,940

CONSOLIDATED STATEMENTS OF UNAU

CONSOLIDATED STATEMENTS OF UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Income Statement [Abstract]
Revenue	$ 721,661	$ 1,719,148
Cost of Goods Sold	133,618	870,621
Gross Profit	588,043	848,527
Operating expenses
Research and development	338,734	180,067
Bad debt expense	10,981	0
General and administrative	4,787,039	2,272,641
Total operating expenses	5,316,754	2,452,708
Operating Loss	(4,548,711)	(1,604,181)
Other Income (Expense):
Interest expense	(2,516,113)	(165,716)
Interest income	452	6,660
Changes in fair value of contingent purchase consideration	0	19,545,098
Change in fair value of derivative liability	(1,836,208)	0
Loss on settlement of debt	(403,214)	0
Other income, net	(8,753)	3,886
Net (Loss) Income	(9,312,547)	17,785,747
Net loss attributable to non-controlling interests	(186,602)	(88,256)
Net (Loss) Income Available to Common Stockholders	$ (9,125,945)	$ 17,874,003
Basic	$ (0.17)	$ 0.78
Diluted	$ (0.17)	$ 0.33
Basic	53,186,407	22,806,777
Diluted	53,186,407	54,699,198
Comprehensive (loss) income:
Net (loss) income	$ (9,125,945)	$ 17,874,003
Change in foreign currency translation adjustments	(294)	1,626
Comprehensive (Loss) Income Available to Common Stockholders	$ (9,126,239)	$ 17,875,629

UNAUDITED CONDENSED INTERIM C_3

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Preferred Stock	Common Stock	CommonStockPayable	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Sub Total	Noncontrolling Interest	Total
Balance at Jul. 31, 2018	$ 4	$ 22,430	$ 2,168,951	$ 368,388,265	$ (409,386,468)	$ 798,422	$ (38,008,396)	$ (5,576,272)	$ (43,584,668)
Balance (in shares) at Jul. 31, 2018	79,590	22,430,121
Investment in subsidiary by noncontrolling interest								91,027	91,027
Issuance of common stock payable		$ 5,997	(1,917,334)	1,911,337
Issuance of common stock payable (in shares)		5,996,928
Issuance of stock options				103,194			103,194		103,194
Currency translation adjustment						1,626	1,626		1,626
Net Income (loss)					17,874,003		17,874,003	(88,256)	17,785,747
Balance at Oct. 31, 2018	$ 4	$ 28,427	251,617	370,402,796	(391,512,465)	800,048	(20,029,573)	(5,573,501)	(25,603,074)
Balance (in shares) at Oct. 31, 2018	79,590	28,427,049
Balance at Jul. 31, 2019		$ 62,290		408,566,529	(418,727,875)	797,216	(9,301,840)	16,974,439	7,672,599
Balance (in shares) at Jul. 31, 2019		62,290,940
Stock compensation expense				787,458			787,458		787,458
Issuance of common stock payable		$ 297		921,598			921,895		921,895
Issuance of common stock payable (in shares)		296,793
Conversion of debt to equity		$ 1,164		1,735,673			1,736,837		$ 1,736,837
Conversion of debt to equity (in shares)		1,164,190							1,164,190
Issuance of common stock for acquisitions		$ 960		1,150,992			1,151,952		$ 1,151,952
Issuance of common stock for acquisitions (in shares)		960,000
Reduction of derivative liabilities				1,911,487			1,911,487		1,911,487
Cancellation of shares		$ (20,376)		20,376
Cancellation of shares (in shares)		(20,375,900)
Purchase of shares in subsidiary				1,987,390			1,987,390	(1,987,390)
Currency translation adjustment						(294)	(294)		(294)
Net Income (loss)					(9,125,945)		(9,125,945)	(186,602)	(9,312,547)
Balance at Oct. 31, 2019		$ 44,335		$ 417,081,503	$ (427,853,820)	$ 796,922	$ (9,931,060)	$ 14,800,447	$ 4,869,387
Balance (in shares) at Oct. 31, 2019		44,336,023

UNAUDITED CONDENSED INTERIM C_4

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) Income	$ (9,312,547)	$ 17,785,747
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	203,273	25,664
Amortization of operating lease right-of-use assets	18,887	0
Stock compensation expense	787,458	103,194
Loss on settlement of debt	403,214	0
Changes in fair value of contingent purchase consideration	0	(19,545,097)
Amortization of debt discount	2,065,835	0
Change in fair value of derivative liabilities - convertible notes	(1,131,156)	0
Change in fair value of derivative liabilities - convertible warrants	(66,456)	0
Change in fair value of derivative liabilities - downside protection	3,033,820	0
Bad debt expense	10,981	0
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	4,024	721
Inventory	(98,184)	242,235
Accounts payable and accrued expenses	2,366,230	1,006,344
Loans from related parties	52,912	0
Other current assets	(163,596)	24,605
Other current liabilities	(18,500)	0
Net cash used in operating activities	(1,843,805)	(356,587)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(4,451)	(6,168)
Cash received in acquisition of a business, net of cash paid	49,305	1,052,537
Net cash provided by investing activities	44,854	1,046,369
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of notes payable	(935,731)	0
Proceeds from note payable	2,976,745	534,940
Investment in subsidiary by noncontrolling interest	0	91,027
Net cash provided by financing activities	2,041,014	625,967
Effects of currency translation on cash and cash equivalents	(294)	1,626
Net increase in cash and cash equivalents	241,769	1,317,375
Cash and cash equivalents, beginning of period	298,485	1,046,365
Cash and cash equivalents, end of period	540,254	2,363,740
Supplemental Disclosure of Cash Flow Information
Reduction of derivative liabilities	1,911,487	0
Discount on derivative liability upon issuance of debt	1,052,349	0
Issuance of common stock for conversion of debt	1,694,851	0
Recording of Right of Use Asset and Liability	116,440	0
Increase common stock payable	14,500	0
Issuance of shares-common stock payable	921,895	0
Note payable issued for acquisition of a business	$ 0	$ 15,000,000

Organization of Business and Go

Organization of Business and Going Concern	3 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Organization of Business and Going Concern	Note 1 – Organization of Business and Going Concern: Generex Biotechnology Corporation (“Generex” or the “Company”), was formed in the State of Delaware on September 4, 1997 and its year-end is July 31. It is engaged primarily in the research and development of drug delivery systems and the use of the Company’s proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator; and through the Company’s wholly-owned subsidiary, Antigen Express, Inc. (“Antigen”), has undertaken work on immunomedicines incorporating proprietary vaccine formulations. On January 18, 2017, the Company closed an Acquisition Agreement pursuant to which the Company acquired a 51% interest in NuGenerex Diagnostics LLC “NGDx,” formerly known as Hema Diagnostic Systems, LLC, a Florida limited liability company established in December 2000 to market and distribute rapid test devices including infectious diseases. Since 2002, NGDx has been developing an expanding line of rapid diagnostic tests (RDTs) including such diseases as Human Immunodeficiency Virus (HIV) – 1/2, tuberculosis, malaria, hepatitis, syphilis, typhoid and dengue as well as other infectious diseases. Subsequently, on December 1, 2018, the Company closed the acquisition of the remaining 49% interest in NGDx to become a wholly owned subsidiary of the Company. On October 3, 2018, the Company entered into an Asset Purchase Agreement with Veneto Holdings, L.L.C. (“Veneto”) to purchase certain assets of Veneto and its subsidiaries. The Agreement bifurcated the closing. On October 3, 2018 (the “First Closing”), the Company purchased substantially all the operating assets of Veneto including (a)system of dispensing pharmacies, (b) one central adjudicating pharmacy, (c) a wholesale pharmaceutical purchasing company, and (d) an in-network laboratory. On November 1, 2018 the Company consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto’s management services organization business and two additional ancillary services. In March 2019, the Company changed its business model to no longer utilize their existing pharmacies. Going forward Veneto will conduct business exclusively through their management services organization (“MSO”) and by entering into more ancillary provider service agreements with third party pharmacies as an effort to reduce fixed costs and salaries. This was made practicable due to the decrease in overall script volume coupled with delays in the Company being able to receive operating licenses from various government agencies. On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product. In the first quarter of 2020 the Company acquired increased its ownership of Olaregen to 77%. On August 1, 2019, the Company, through its wholly owned subsidiary NDS, closed on Asset Purchase Agreements (the “APAs”) for the purchase of substantially all the operating assets of MediSource Partners, LLC (“MediSource”) and Pantheon Medical - Foot & Ankle, LLC (“Pantheon”) (Note – 16). MediSource contracts with vendors (including Pantheon) for nationwide distribution of implants and devices for spine, hips, knees, foot, ankle, hand, and wrist surgeries. Additional product lines include biologics (blood, bone, tissue, and stem cells), durable medical equipment, and soft goods. MediSource also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at the time of surgery. Pantheon sells a physician friendly, “all-in-one,” integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Over the next three years, Pantheon expects to develop and submit several new product lines to the FDA, which will include cannulated surgical screws and surgical staples, as well as a proprietary Hammertoe System. Going Concern The accompanying unaudited condensed interim consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. The Company has experienced recurring net losses and negative cash flows from operations since inception and has an accumulated deficit of approximately $428 million and a working capital deficiency of approximately $32.5 million at October 31, 2019. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to implement its new investment acquisition plans. Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, and issuances of debt and convertible debt instruments. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the balance sheet date. There are no assurances that such additional funding will be achieved and that the Company will succeed in its future operations. The unaudited condensed interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s inability to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition and business prospects will be materially and adversely affected, and the Company may have to cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies: Basis of Presentation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated. Operating results for the three months ended October 31, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2020. The balance sheet at October 31, 2019 does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2019 as filed with the U.S. Securities and Exchange Commission (“SEC”). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates. Business Combinations Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued, or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any non-controlling interest, over the fair value of the identifiable net assets acquired. Revenue Recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements. Revenue from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition have been met. Revenue from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services model, laboratory services are provided prior to insurance company approval; as a result, the seller’s price to buyer is not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected revenues associated with similar tests and recognizes the revenue when testing results have been provided (v). Revenue from NGDx is recognized upon payment at the time the product(s) is released (shipment delivered using a common carrier), and the control is transferred which is simultaneous to when payment received and accepted. Revenue from product sales of Olaregen’s Excellagen® is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, contractual arrangement and specific known market events and trends. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. Revenue from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements in place typically specify that a percentage of the gross margin associated with the third-parties’ sales that the Company facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties’ sales of such products (iv). Like pharmacy services described above, revenue is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel) (v). Provisions for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based on historical and anticipated rates. The Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis. In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The Company’s obligations under its client contracts for which revenues are reported using the gross method are separate and distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products sold, regardless of whether the Company is paid by its clients. The Company’s responsibilities under its client contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing. Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts under which the Company acts as an agent, revenue is recognized using the net method. Adoption of New Accounting Standards We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effective dates during the periods reported and in future periods. The Company does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. In February 2016, the FASB issued ASU No. 2016-02, Leases Recently Issued Accounting Standards In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Topic 480, Distinguishing Liabilities from Equity In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement”, which adds disclosure requirements to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on consolidated financial statements.

Loans from Related Parties

Loans from Related Parties	3 Months Ended
	Oct. 31, 2019
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract]
Loans from Related Parties	Note 3 - Loans from Related Parties Pursuant to the acquisitions of Regentys, the Company assumed $19,700 of loans payable to Regentys shareholders. As part of the assets purchase agreement for Pantheon, the Company acquired 50% of the open accounts receivable. The amount collected on accounts receivable excluded from the acquisition, that is due to the prior owner of Pantheon, was $52,912. The balance of loans from related parties was $72,612 as of October 31, 2019.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Oct. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 4 - Commitments and Contingencies: Pending Litigation The Company is a defendant in one legal proceeding relating to alleged breach of contract and claims against certain of the Company’s original buccal delivery patents. The Company is also a defendant in two legal proceedings brought by a former executive officer and her affiliate. These legal proceedings have been reported in the Company’s prior periodic reports. No activity has occurred in these cases in several years, and the Company now considers them dormant. In December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest. The Company responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such spinout. Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each party’s counsel until payment of the settlement amount. Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court. If the Company fails to make the payment following completion of any post-spinout financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000. This has been accrued in the unaudited condensed interim consolidated financial statements. On August 22, 2017, Generex received a letter from counsel for Three Brothers Trading LLC, d/b/a Alternative Execution Group (“AEXG”), claiming breach of a Memorandum of Understanding (“MOU”) between Generex and AEXG. The MOU related to AEXG referring potential financing candidate to Generex. The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs. On December 2, 2018, an arbitrator awarded Three Brothers Trading LLC, d/b/a Alternative Execution Group (“AEXG”) an aggregate of $315,695 in damages, costs and fees as well as warrants exercisable for 84,000 shares of Generex Common Stock at an exercise price of $2.50 per share. The awards were made pursuant to claims under a Memorandum of Understanding (“MOU”) between Generex and AEXG related to AEXG referring potential financing candidate to Generex. AEXG filed a petition to confirm the arbitrator’s award in the United States District Court for the Southern District of New York. The petition includes a demand of $3,300,360 as the value of the Warrants. The arbitrator did not award the specific amount of $3.3 million, but only liquidated damages in the amount of $220,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees. The petition to confirm the arbitrator’s award and Generex’s opposition were remanded by the Court to the arbitrator and returned for clarification. The arbitrator stated that he was unable to add any clarification, as he did not take evidence on the issue of warrant valuation. The parties are awaiting the court’s response to the Arbitrator’s statement. As of October 31, 2019, the value of the warrants have a market value of $65,613. Between the warrants and the $220,000 of liquidated damages, the Company has accrued $285,613 related to this matter. On June 28, 2018, the Company was named in respect of a claim by Burrard Pharmaceutical Enterprises Ltd. and Moa’yeri Kayhan for unspecified damages and other remedies issued by the Supreme Court of British Columbia. The claim is made in connection with one advanced against Burrard and Kayhan by Middle East Pharmaceutical Factory L.L.C., a foreign corporation, for fraudulent or negligent misrepresentation. Middle East alleges that it was misled by Burrard and Kayhan into believing that Burrard had rights to distribute Generex product in the Middle East. Burrard and Kayhan allege that they did have rights in that regard, which the Company denies. The matter remains at the pleadings stage and the Company is investigating the facts. On October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold its Note Due October 26, 2019 (“Note”) in the principal amount of $682,000 . On March 21, 2019 Compass Bank filed suit against NuGenerex Distributions Solutions 2, L.L.C. in the District Court of Dallas County, Texas requesting damages of $3,413,000. In connection with the closing of the Veneto acquisition, Compass Bank had a lien on certain assets that were supposed to be transferred into the ownership of NuGenerex, a subsidiary of Generex. Those assets were never transferred due to regulatory impositions. Generex had listed Compass Bank as an intended third party beneficiary to the transaction in relation to the assets liened and Veneto ceased payments upon the loan which the lien generated from. Compass bank filed suit against 6 parties involved in the transaction to collect on the loan, including NuGenerex. NuGenerex’s position is the contract was frustrated by the assets that were liened were never transferred, NuGenerex did not receive any benefit from the agreement, and thus NuGenerex is not responsible to Compass Bank for repayment of a loan on assets not transferred. Generex intends to implead Brooks Houghton for indemnification who was retained to perform due diligence on the transaction. In May 2019 Brooks Houghton threatened litigation by way of a FINRA Dispute Resolution. Brooks Houghton, who the managing representative is Mr. Centonfanti a prior board member, was under contract to perform due diligence on the Veneto transaction, as well as other unrelated items. The Veneto transaction closed three times, each time with a reduction in price due to material negative circumstances. Brook Houghton, who was under contract to perform due diligence, claims their fee should be paid on the initial closing price not the ultimate resolution of the matter. The company offered to compensate Brooks Houghton pursuant to agreement, 3% on the most recent closing price for Veneto for which Brooks Houghton may have performed some level of work on, payable in kind, and Brooks Houghton declined the offer. Brooks Houghton is claiming $450,000 for the first closing of Veneto, $714,000 for the second closing of Veneto, $882,353 for the Regentys acquisition, and $705,882 for Olaregen. The company is awaiting service. As of October 31, 2019, the Company has accrued for the full $2,752,235 balance. With respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses its position both with respect to accrued liabilities and other potential exposures. Commitments Intellectual Property In connection with the Company’s acquisition of Olaregen, intellectual property was acquired that had a valuation of $650,000 prior to being acquired and revalued. This initial $650,000 valuation represented the initial payment remitted by Olaregen in accordance with the $4 million signed commitment agreement entered into with Activation Therapeutics, Inc. The remaining $3.35 million balance is to be paid in quarterly installments equal to 10% of quarterly net sales generated by Activation Therapeutics assuming the Exellagen average selling price per unit exceeds $800. In the event that the average selling price per unit is less than $800 per unit, cost of goods sold shall be excluded from the computation of net sales.

Leases

Leases	3 Months Ended
	Oct. 31, 2019
Leases [Abstract]
Leases	Note 5 – Leases The Company has various operating lease agreements with terms up to 2 years, including leases of office space. Some leases include purchase, termination or extension options for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. The Company adopted ASC 842 effective August 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update: • The option to not reassess prior conclusions related to the identification, classification and accounting for initial direct costs for leases that commenced prior to January 1, 2019. • Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less; and • The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment. • The package of practical expedients applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, the Company uses a discount rate based on its incremental borrowing rate, which is determined using the average of borrowing rates explicitly stated in the Company’s convertible debt. The Company’s weighted-average remaining lease term relating to its operating leases is 1.3 years, with a weighted-average discount rate of 9.5%. The Company incurred lease expense for its operating leases of $21,508 for three months ended October 31, 2019. The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases as of October 31, 2019: Maturity of Operating Lease Liabilities 2019 $ 64,801 2020 39,879 2021 — 2022 — 2023 — Thereafter $ — Total undiscounted operating lease payments $ 104,680 Less: Imputed interest 6,740 Present value of operating lease liabilities $ 97,940

Inventory

Inventory	3 Months Ended
	Oct. 31, 2019
Inventory Disclosure [Abstract]
Inventory	Note 6 – Inventory Inventory consists of the following components: October 31, July 31, 2019 2019 Raw materials $ 74,444 $ 77,782 Finished goods 652,819 285,226 Total Inventory $ 727,263 $ 363,008

Property and Equipment

Property and Equipment	3 Months Ended
	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment Property and equipment, net consisted of the following: October 31, July 31, 2019 2019 Computers and technological assets $ 163,168 $ 163,168 Machinery and equipment 500,576 386,929 Furniture and fixtures 89,123 73,227 Leasehold Improvements 16,596 16,596 769,463 639,920 Less accumulated depreciation (237,575 ) (139,927 ) $ 531,888 $ 499,993 Depreciation expense related to property and equipment for the three months ended October 31, 2019 and October 31, 2018 was $48,847 and $25,664, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 8 – Goodwill and Intangible Assets Intangible assets consist of the following at: October 31, July 31, 2019 2019 In-Process Research & Development $ 8,761,427 $ 8,761,427 Non-compete agreements 1,566,700 1,210,000 Developed software/technology 172,500 131,000 Vendor agreements and other intangibles 775,674 51,274 11,276,301 10,153,701 Less accumulated amortization (473,859 ) (319,432 ) $ 10,802,442 $ 9,834,269 Intangible assets are generally amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing the in-process research and development until it becomes commercially viable and placed in service. At the time when the intangible assets are placed in service the Company will determine a useful life. Amortization expense amounted to $154,426 and $646 for the three months ended October 31, 2019 and October 31, 2018, respectively. The remaining estimated amortization expense for the next five years and thereafter is as follows: Year Ending July 31, Amount 2020 $ 570,708 2021 616,744 2022 246,324 2023 94,511 2024 68,491 Thereafter 444,658 $ 2,041,435 Changes in the value of goodwill: Balance as of July 31, 2019 $ 38,297,573 Acquisition of MediSource and Pantheon 603,553 Balance as of October 31, 2019 $ 38,901,126

Notes Payable

Notes Payable	3 Months Ended
	Oct. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	Note 9 – Notes Payable On October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold its Note Due October 26, 2019 (“Note”) in the principal amount of $682,000 . On January 24, 2019, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company agreed to sell and sold its convertible note bearing interest at 10% per annum (the “Notes”) in the principal amount of $530,000. The purchase price of the Notes was $505,000 and the remaining $25,000 of principal amount represents original issue discount. Pursuant to the Securities Purchase Agreement, Generex also sold warrants to the investors to purchase 30,285 shares of common stock with the fair value of the warrants as of the date of issuance in excess of the Notes resulting in full discount of the Notes. In February 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company agreed to sell and sold each investor a $750,000 convertible note bearing interest at 10% per annum (the “Notes”). The total purchase price of the Notes was $1,425,000 and the remaining $75,000 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of a price determined as of the date of closing; and 70% of the lowest trading price of the common stock on the ten days prior to conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 102,143 shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Notes (Note 14) resulting in full discount of the Notes. One of the notes went into default during the quarter. Pursuant to a settlement agreement, the Company agreed to settle the debt by making a $900,000 payment and converting $350,000 of the remaining principal into common stock of the Company. The Company recognized a loss on settlement of debt of $403,214. In April 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company agreed to sell and sold convertible notes bearing interest at 10% per annum (the “Notes”) in the aggregate principal amount of $1,060,000. The purchase price of the Notes was $1,000,000 and the remaining $60,000 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of a price determined as of the date of closing; and 70% of the lowest trading price of the common stock on the ten days prior to conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase Agreements, Generex also sold warrants to the investors to purchase up to an aggregate 176,968 shares of common stock. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the Notes (Note 14) resulting in full discount of the Notes. During the quarter, $110,000 of principal was converted into common stock of the Company, leaving a remaining principal balance of $950,000 at October 31, 2019. In May 2019, the Company consummated a Stock Purchase Agreement entered into January 14, 2019 to which the Company agreed to sell and sold $2,000,000 Promissory Note bearing interest at 7% per annum (the “Notes”) originally due and payable on August 1, 2019. The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated. In July 2019, Generex entered into Securities Purchase Agreements with two investors pursuant to which the Company agreed to sell and sold convertible notes bearing interest at 9% per annum (the “Notes”) in the aggregate principal amount of $446,600. The purchase price of the Notes was $400,000 and the remaining $46,600 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: the lesser of a price determined as of the date of closing; and 80% of the lowest volume weighted average trading price of the common stock on the ten days prior to conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $206,548 and was recorded as a discount of the Notes. In August 2019, the Company borrowed $1,000,000 from an investor, bearing 10% interest per annum, with an original issue discount of $150,000. $1,150,000 is due in one year from the date of issuance. In August and September 2019, the Company entered into Securities Purchase Agreements with three investors pursuant to which the Company agreed to sell and sold convertible notes bearing interest between 9% and 10% per annum (the “Notes”) in the aggregate principal amount of $2,222,500. The purchase price of the Notes was $1,976,745 and the remaining $245,755 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: 80% of the lowest trading price of the common stock on the ten or twenty days prior to conversion. The embedded conversion feature of these Notes was deemed to require bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $1,052,349 and was recorded as a discount of the Notes. For the quarter ending October 31, 2019, amortization of debt discount was $2,065,835 leaving a remaining debt discount balance as of October 31, 2019 of $1,473,842. On December 28, 2017, the Company through its wholly owned subsidiary NuGenerex, completed the acquisition of the assets and 100% of the membership interests of two pre-operational pharmacies, Empire State Pharmacy Holdings, LLC and Grainland Pharmacy Holdings, LLC, pursuant to the bills of sale for a consideration of $320,000 Promissory Note due and payable in full on June 28, 2018 bearing an annual interest rate of 3%. The note was extended by six months and set to mature with the same terms on December 28, 2018. The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated. Pursuant to the second closing of the acquisition of certain operating assets of Veneto Holdings, L.L.C. and its affiliates, Generex’s wholly owned subsidiary agreed to assume outstanding debt of Veneto subsidiaries to Compass Bank, including obligations under a term loan and a revolving line of credit. Claiming three separate types of default, Compass Bank has demanded payment in full of amounts due under the term loan and revolving line of credit, in an aggregate amount of approximately $3,413,000. Generex believes it has defenses to such demand, including that the bank was not an intended beneficiary of the subsidiary’s agreement to assume the debt. Pursuant to its acquisition of Regentys, the Company inherited convertible notes with several investors which collectively held a principal plus of $615,000 as of the date of acquisition. As of October 31, 2019, the remaining principal balance was $349,656 with an unamortized debt discount balance of $3,719. These notes have an accrued interest balance of $39,191 as of October 31, 2019.

Derivative Liability

Derivative Liability	3 Months Ended
	Oct. 31, 2019
Notes to Financial Statements
Derivative Liability	Note 10 – Derivative Liability The Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted, and all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. Based on the various convertible notes described in Note 13, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows as of October 31, 2019: following table presents the activity for derivative liabilities measured at estimated fair value: Derivative Liability - Convertible Notes Derivative Liability - Warrants Derivative Liability - Downside Protection Total Balance as of July 31, 2019 4,156,196 325,250 3,338,836 7,820,282 Additions during the period 1,021,996 30,353 — 1,052,349 Change in fair value (1,131,157 ) (66,456 ) 3,033,820 1,836,207 Change due to exercise / redemptions (1,875,052 ) (36,432 ) — (1,911,484 ) Balance as of October 31, 2019 $ 2,171,983 $ 252,715 $ 6,372,656 $ 8, 797,354

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Oct. 31, 2019
Equity [Abstract]
Stockholders' Equity	Note 11 - Stockholders’ Equity: Common Stock On November 13, 2018, the Company declared a stock dividend on its outstanding Common Stock for stockholders of record date to be determined (the “Record Date”). As a result, all stockholders on the Record Date received twenty new shares of Common Stock for each share of Common Stock owned by them as of that date. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the condensed interim consolidated financial statements. During the three months ended October 31, 2019, 296,793 shares of common stock payable were issued. As of October 31, 2019, 286,377 shares remain to be issued resulting in common stock payable $215,793. During the first quarter of 2020, the Company issued 1,164,190 shares of common stock for the conversion of approximately $1,736,900 of debt. In August 2019, the Company issued 400,000 and 560,000 shares of common stock valued at $2.50 per share for the acquisition of MediSource and Pantheon, respectively. On September 12, 2019, 20,375,900 outstanding shares of common stock were cancelled by the Company held by Joe Moscato TTEE Friends of Generex Biotechnology Investment Trust U/A/D 4/2/2019, a trust formed for the benefit the Company and any 80% controlled subsidiary of the Company by several shareholders contributing in the aggregate 33,175,900 shares of the Company’s Common Stock and 8,293,975 shares of Antigen Express, Inc, d/b/a NuGenerex Immuno-Oncology commons shares (the “Friends of Generex Trust”), similar to the Stock Control Agreement previously entered into by the same shareholders on December 1, 2018 filed in an 8-K filed on December 3, 2019, incorporated herein by reference. Non-controlling Interest Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of October 31, 2019, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest. Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. On August 16, 2019, the Company entered into a Share Exchange Agreement to purchase an additional 900,000 shares of common stock in Olaregen from other shareholders of Olaregen in exchange for 1,905,912 shares of Generex common stock contributed and provided by the Friends of Generex Trust and 476,478 shares of Antigen common stock contributed and provided by the Friends of Generex Trust. In September 2019, the Company converted all of the Series A Preferred Stock of Olaregen into common stock of Olaregen. On February 25, 2019, we issued a stock dividend to our shareholders, whereby our shareholders received one (1) share of NGIO for every four (4) shares of our stock held on the dividend date. As of October 31, 2019, Olaregen had a total of 6,236,390 shares of common stock and zero Series A voting preferred stock outstanding. As such, there are 1,461,075 of shares that belong to non-controlling interest shareholders which represents a 23.43% non-controlling interest. On November 1, 2018, the Company completed its second closing of Veneto Holdings, L.L.C. (“Veneto”) which granted the Company Rapport Services, LLC (“Rapport”) through the ownership of the units of Class B membership interests providing control of Rapport as only the Class B Member is entitled to elect the nominees to the Board of Managers, which constitute a one percent (1%) ownership in Rapport. The remaining interests represent a 99% non-controlling interest.

Redeemable Non-Controlling Inte

Redeemable Non-Controlling Interest	3 Months Ended
	Oct. 31, 2019
Notes to Financial Statements
Redeemable Non-Controlling Interest	Note 12 – Redeemable Non-Controlling Interest: Pursuant to the Company’s acquisition of 51% of the outstanding capital stock of Regentys, Regentys had authorized 7,500,000 shares of redeemable Series A Convertible Preferred Stock (“Preferred Stock A”), with a par value of $0.0001 and redemption value of $0.65 per share of which 2,793,192 Preferred Stock A was outstanding as of the date of acquisition and as of October 31, 2019. Preferred Stock may be converted into common stock at the initial conversion ratio of 1:1 which ratio shall be adjusted in accordance with stock dividends, splits, combinations and other similar events, including the sale of additional shares of common or preferred stock and the holders of Preferred Stock A are entitled to vote, together with the holders of Regentys common stock, on all matters submitted to stockholders of Regentys for a vote. At any time after November 1, 2026, the holders of the Company’s Series A Preferred Stock will have the right to require the Company to redeem all or a portion of their shares for cash at a redemption price equal to its liquidation value. Accordingly, this Preferred Stock A was valued to be $4,073,898 at the time of acquisition of Regentys and reclassified as Redeemable Non-Controlling Interest outside of stockholders’ deficit on the consolidated balance sheets.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Oct. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 13 - Stock-Based Compensation Stock Option Plans As of October 31, 2019, the Company had two stockholder-approved stock incentive plans under which shares and options exercisable for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 2,835,000 shares of common stock are reserved for issuance under the 2006 Stock Plan as amended (the 2006 Plan) and 240,000,000 shares of common stock reserved for issuance under the 2017 Stock Option Plan (the 2017 Plan). At October 31, 2019, there were 2,823,450 and 231,149,875 the 2006 Plan and 2017 Plan, respectively. The Company issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance of restricted shares. The 2006 and 2017 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Board. The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides for restricted stock grants. The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Options Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2019 7,988,675 $ 0.84 7.21 $ 15,961,391 Granted 1,003,000 $ 2.09 4.92 — Forfeited or expired (130,000 ) $ 1.11 7.65 — Exercised — — — — Outstanding - October 31, 2019 8,861,675 $ 0.98 6.71 $ 5,859,392 The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on October 31, 2019. The market values as of October 31, 2019 was $1.53 based on the closing bid price for October 31, 2019. There were 3,540,675 vested common stock options under the Plan as of October 31, 2019. The compensation expense was $787,458 for the three months ended October 31, 2019. The Company had $4,256,191 of unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan at October 31, 2019 to be recognized over an average of 2.67 years. The Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes option-pricing models requires the Company to make predictive assumptions regarding future stock price volatility, recipient exercise behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the expected term of the option. The following assumptions were used in the Black-Scholes option-pricing model: October 31, Exercise price $2.01 – 2.09 Time to expiration 5 years Risk-free interest rate 1.51% - 1.59% Estimated volatility 153.4 % Expected dividend — Stock price at valuation date $2.01 – 2.09 During 2019, the Company established a Direct Stock Purchase Plan (“2019 Plan”) pursuant to which eligible participants may acquire shares of common stock in lieu of certain cash obligations otherwise owed to participants during the 2019 calendar year. The 2019 Plan will automatically terminate on December 31, 2019. There was a total of 1,200,000 shares of common stock reserved under the plan of which no shares have been issues.

Warrants

Warrants	3 Months Ended
	Oct. 31, 2019
Warrants Abstract
Warrants	Note 14 - Warrants A summary of the Company’s warrant activities is as follows: Number of Warrants Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2019 15,399,681 $ 2.53 0.40 $ 4,500,000 Issued 62,857 3.50 5.01 — Forfeited (57,143 ) 3.50 — — Outstanding - October 31, 2019 15,405,395 $ 2.52 0.18 $ — During the three months ended October 31, 2019, the Company issued 62,857 to investors of convertible notes and 57,143 warrants were forfeited upon settlement of a note. All the warrants issued vested immediately upon issuance. Additionally, 84,000 warrants are to be issued to AEXG in connection with an arbitrator’s award (Note 4).

Net Income Per Share (EPS)

Net Income Per Share (EPS)	3 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Net Income Per Share (EPS)	Note 15 - Net Income Per Share (“EPS”): Basic net income or loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. Three Months Ended October 31, 2019 2018 Weighted average number of common shares outstanding - Basic 53,186,407 22,806,777 Potentially dilutive common stock equivalents — 31,892,421 Weighted average number of common and equivalent shares outstanding - Diluted 53,186,407 54,699,198 The following table provides weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, for the three months ended October 31, 2019 and 2018, respectively. Three Months Ended October 31, 2019 2018 Series H Convertible Preferred Stock — 25,200,000 Series I Convertible Preferred Stock — 6,636,000 Convertible debt 3,744,548 — Stock options 8,871,675 2,747,850 Warrants 15,405,395 — Total 28,021,618 34,583,850

Acquisitions

Acquisitions	3 Months Ended
	Oct. 31, 2019
Business Combinations [Abstract]
Acquisitions	Note 16 – Acquisitions: MediSource and Pantheon: On August 1, 2019, the Company, through its wholly owned subsidiary NDS, closed on Asset Purchase Agreements (the “APAs”) for the purchase of substantially all the operating assets of MediSource Partners, LLC (“MediSource”) and Pantheon Medical - Foot & Ankle, LLC (“Pantheon”). MediSource contracts with vendors (including Pantheon) for nationwide distribution of implants and devices for spine, hips, knees, foot, ankle, hand, and wrist surgeries. Additional product lines include biologics (blood, bone, tissue, and stem cells), durable medical equipment, and soft goods. MediSource also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at the time of surgery. Pantheon sells a physician friendly, “all-in-one,” integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Over the next three years, Pantheon expects to develop and submit several new product lines to the FDA, which will include cannulated surgical screws and surgical staples, as well as a proprietary Hammertoe System. The goal in acquiring these operating companies is that they expect to provide multiple and significant revenue streams through delivery of patient-focused healthcare products and services, thus generating value and ultimately creating goodwill upon acquisition. Travis H. Bird was the CEO and principal owner of both Pantheon and MediSource. Under the APAs: • Generex will issue 400,000 shares of common stock in exchange for the Pantheon assets, and 560,000 shares of common stock in exchange for the MediSource assets. • Generex and NDS will pay up to $700,000 in cash to Pantheon as an earn out payment. No payment will be made unless the business conducted by NDS using the former Pantheon assets has EBITDA in the twelve months following closing in excess of $500,000. If the Pantheon business’s EBITDA meets or exceeds $1,000,000, the entire $700,000 will be paid. If the Pantheon business’s EBITDA exceeds $500,000 but is less than $1,000,000, a pro rata portion of the $700,000 earn-out will be paid. • Generex and NDS will pay up to $500,000 in cash to MediSource as an earn out payment. No payment will be made unless the business conducted by NDS using the former MediSource assets has EBITDA in the twelve months following closing in excess of $130,000. If the MediSource business’s EBITDA meets or exceeds $500,000, the entire $500,000 will be paid. If the MediSource business’s EBITDA exceeds $130,000 but is less than $500,000, a pro rata portion of the $500,000 earn-out will be paid. • In the event the EBITDA targets are met for one or both MediSource and Pantheon, Travis Bird will receive sales commissions equal to 15% of net sales during the first year following closing, and 10% of net sales during the second year. • Both MediSource and Pantheon agreed to waive the 1:1 stock dividend Generex announced it will issue if Generex is listed on NASDAQ. • Each of Pantheon and MediSource will retain 50% of its cash on hand and 50% of its accounts receivable, with the remainder transferred to NDS at closing. • Generex and NDS will not assume any Pantheon or MediSource liabilities except for post-closing obligations under assumed contracts. • Pantheon and MediSource will not transfer their Medicare and Medicaid numbers. At closing, Mr. Bird will enter into an 18-month consulting agreement with NDS. As compensation, Mr. Bird will receive Generex common stock with a value of $250,000, as well as monthly payments equaling $97,222. The monthly payments shall be paid from any available cash from the operations of Pantheon and MediSource. Any remaining balance of such monthly payments will consist of common stock. The agreement specifies the shares are to be freely tradeable. In addition, Mr. Travis will agree to fully assign and exchange any ownership rights in any new technology he develops with the Company, in exchange for a payment of $500,000 in value of common stock for each completed item submitted to the FDA. The Company accounted for the Acquisition of MediSource and Pantheon as a business combination using the purchase method of accounting as prescribed in Accounting Standards Codification 805, Business Combinations (“ASC 805”) and ASC 820 – Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 805 and ASC 820, we used our best estimates and assumptions to accurately assign fair value to the tangible assets acquired, identifiable intangible assets and liabilities assumed as of the acquisition dates. Goodwill as of the acquisition date is measured as the excess of purchase consideration over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. Fair Value of the MediSource Acquisition The following table summarizes the allocation of the preliminary purchase price as of the MediSource acquisition: Preliminary Cash and cash equivalents $ 13,895 Other current assets 11,864 Property and equipment, net 8,992 Accounts payable and accrued liabilities (31,439 ) Net Tangible Assets $ 3,312 Tradename / Trademarks 47,600 Business Contracts 346,800 Non-Competes 124,600 Total Fair Value of Assets Acquired 522,312 Consideration: Fair value of common stock 479,980 Contingent consideration 409,790 Consideration included in consulting agreement 104,168 Total Purchase Price 993,938 Goodwill $ 471,626 Fair Value of the Pantheon Acquisition The following table summarizes the allocation of the preliminary purchase price as of the Pantheon acquisition: Preliminary Cash and cash equivalents $ 35,410 Accounts receivable 133,269 Prepaid expenses 3,336 Inventory 266,071 Medical Equipment, net 67,299 Accounts payable (53,242 ) Accrued liabilities (15,573 ) Net Tangible Assets $ 436,570 Tradename / Trademarks 55,400 IP/Technology 41,500 Non-compete agreement 232,100 Customer Base 274,600 Total assets acquired $ 1,040,170 Consideration: Fair value of common stock 671,972 Contingent consideration 354,292 Consideration included in consulting agreement 145,833 Goodwill $ 131,927 The components of the acquired intangible assets were as follows: Preliminary Average Estimated Life Tradename / Trademarks $ 103,000 15 IP/Technology 41,500 5 Business Contracts 346,800 15 Customer Base 274,600 10 Non-compete agreement 356,700 3 $ 1,112,600 Unaudited Supplemental Pro Forma Data Unaudited pro forma results of operations for the three months ended October 31, 2019 and 2018 as though the Company acquired MediSource and Pantheon on the first day of each fiscal year are set forth below. Three months Ended October 31, 2019 2018 Revenues $ 721,661 $ 2,141,000 Cost of revenues 133,618 987,409 Gross profit 588,043 1,153,591 Operating expenses 5,136,754 2,629,854 Operating loss (4,548,711 ) (1,476,262 ) Other income (expense) (4,763,836 ) 19,389,944 Net loss $ (9,312,547 ) 17,913,682 Comprehensive net loss $ (9,312,547 ) $ 17,913,682

Income Taxes

Income Taxes	3 Months Ended
	Oct. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Note 17 – Income Taxes: The Company has incurred losses since inception, which have generated net operating loss (“NOL”) carryforwards. The NOL carryforwards arise from both United States and Canadian sources. Pre-tax gain or (loss) arising from domestic operations (United States) were $(9,179,902) and $(11,006,793) for the three months ended October 31, 2019 and the year ended July 31, 2019, respectively. Pre-tax (losses) arising from foreign operations (Canada) were $(10,963) and $(326,461) for the three months ended October 31, 2019 and the year ended July 31, 2019, respectively. As of October 31, 2019, the Company has NOL carryforwards in Generex Biotechnology Corporation of approximately $214 million , of which $196 million will expire in 2020 through 2038, and $17.7 million will not expire. The non-expiring portion is limited to 80% of the current year taxable income of the respective entity. Generex Pharmaceuticals Inc. has NOL carryforwards of approximately $34.3 million, which expire in 2025 through 2040. Antigen Express, Inc. has NOL carryforwards of approximately $36.2 which will expire in 2020 through 2038. Regentys Corporation has NOL carryforwards of approximately $6.1 million, of which $4.9 million will expire in 2033 through 2038. Olaregen Therapeutics, Inc. has NOL carryforwards of $1.3 million which will not expire. Veneto has NOL carryforwards of $8.7 million which will not expire. Some of these loss carryforwards are subject to limitation due to the acquisition of Regentys, Olaregen and Antigen and may be limited in future years due to certain structural ownership changes which have occurred over the last several years related to the Company’s equity and convertible debenture financing transactions. As of October 31, 2019, the Company had no tax benefits which have not been fully allowed for, and no adjustment to its financial position, results of operations or cash flows was required. The Company has deferred tax assets of over $70 million with a full allowance equally to the to the amount of the deferred tax asset. The Company does not expect that unrecognized tax benefits will increase within the next twelve months. During the period ended October 31, 2019, the Company acquired certain assets of MediSource Partners, LLC and Pantheon Medical. The assets are included within Generex Biotechnology Corporation. The Company records interest and penalties related to tax matters within other expense on the accompanying consolidated statement of operations. These amounts are not material to the consolidated financial statements for the years presented. Generally, tax years 2016 to 2019 remain open to examination by the Internal Revenue Agency or other tax jurisdictions to which the Company is subject. The Company’s Canadian tax returns are subject to examination by federal and provincial taxing authorities in Canada. Generally, tax years 2011 to 2019 remain open to examination by the Canada Revenue Agency or other tax jurisdictions to which the Company is subject.

Subsequent Events

Subsequent Events	3 Months Ended
	Oct. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 18 - Subsequent Events: The Company has evaluated subsequent events occurring after the balance sheet date through the date the unaudited condensed interim consolidated financial statements were issued. On November 12, 2019 , the Company’s note holder converted $80,000 of principal and $4,778 of interest into 115,344 shares of common stock. On November 12, 2019 , the Company’s note holder converted $50,000 of principal and $3,096 of interest into 128,561 shares of common stock. On November 14, 2019 , the Company’s note holder converted $50,000 of principal and $2,712 of interest into 80,110 shares of common stock. On November 18, 2019 , the Company entered into three Securities Purchase Agreements with investors pursuant to which the Company agreed to sell and sold three convertible notes bearing interest at 10% per annum in the aggregate principal amount of $275,000. On November 21, 2019 , the Company’s note holder converted $80,000 of principal and $4,493 of interest into 134,865 shares of common stock. On November 21, 2019 , the Company’s note holder converted $100,000 of principal and $6,219 of interest into 169,543 shares of common stock. On November 22, 2019, effective as of November 15, 2019, the Company entered into a Stock Purchase Agreement for the purchase of 51% of the outstanding capital stock of GH Care, Inc. DBA ALTuCELL, Inc.(“ALTuCELL” ) Under the SPA, in exchange for the ALTuCELL Stock, Generex will issue to ALTuCELL 1,600,000 shares of Generex common stock with a down round provision and price floor of $1.25 per share. The Company will also pay $2.5 million in cash of which $112,000 has already been paid. In addition to stock and cash at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCell upon ALTuCell’s attainment of certain milestones. On November 24, 2019 , the Company amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November 30, 2019, in connection with the purchase of Olaregen capital stock. Effective November 24, 2019, the deadline has been extended to January 31, 2020. On November 25, 2019 , the Company amended the Stock Purchase Agreement with Regentys originally on January 7, 2019. Effective November 25, 2019, the remaining three payments of $2,039,001, $2,000,000, and $3,000,000 are all payable on or before December 30, 2019. On November 25, 2019 , the Company entered an Equity Purchase Agreement with an investor to purchase up to $40,00,000 of the Company’s stock at 92% of the market price for the period of five (5) consecutive trading days immediately subject to a put notice on such date on which the Purchase Price is calculated in accordance with the terms and conditions of this Agreement and 1,228,501 shares of common stock (“Commitment Shares”) will be issued to an investor upon signing. On November 27, 2019 , the Company’s note holder converted $100,000 of principal and $6,384 of interest into 202,635 shares of common stock. On November 27, 2019 , the Company’s note holder converted $125,000 of principal and $7,226 of interest into 251,859 shares of common stock. On November 29, 2019 , the Company’s note holder converted $50,000 of principal into 79,214 shares of common stock. On December 5, 2019 , the Company entered an Equity Purchase Agreement with an investor pursuant to which the Company will issue 100,000 shares of common stock to the investor as a commitment fee and a convertible note in the principal amount of $2,200,000. On December 5, 2019 , the Company’s note holder converted $70,000 of principal and $4,621 of interest into 180,682 shares of common stock. On December 5, 2019 , the Company’s note holder converted $75,000 of principal and $4,500 of interest into 192,494 shares of common stock. On December 10, 2019, the Company announced revisions to previously announced stock dividends and approved by the Board of Directors on December 13, 2019 that the previously approved 1:1 common stock dividend shall be restructured to provide for a 2 to 5 stock dividend to shareholders of the Company and for shareholders to also receive an additional 2 to 5 stock dividend of Antigen Express, Inc, d/b/a NuGenerex Immuno-Oncology commons shares; that the record date for the stock dividend be August 30, 2019; and the new pay date for this 2:5 dividend will be January 3, 2020. On December 12, 2019, the Company’s note holder converted $75,000 of principal and $4,756 of interest into 181,007 shares of common stock. On December 12, 2019, the Company’s note holder converted $50,000 of principal and $ 3095.89 of interest into 128,561 shares of common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated. Operating results for the three months ended October 31, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2020. The balance sheet at October 31, 2019 does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2019 as filed with the U.S. Securities and Exchange Commission (“SEC”).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.
Business Combinations	Business Combinations Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued, or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any non-controlling interest, over the fair value of the identifiable net assets acquired.
Revenue Recognition	Revenue Recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements. Revenue from the pharmacy services is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel). At the time of dispensing each pharmacy has a contract with the insurance payor (item (i)); the insurance payor has accepted the claim for reimbursement from the pharmacy (item ii) and informed the pharmacy how much will be paid for the prescription (item (iii)); the insurance payor is now legally obligated to make payment on the accepted claim within a given period proscribed by statute (item (iv)); and, the prescription has been taken from the pharmacy inventory, placed into an individually labeled container specific to the patient, and the patient is able to take possession of the prescription (item (v)). Shipment to or pick up by the patient is the first time that all criteria for revenue recognition have been met. Revenue from the laboratory services is recognized upon the completion of accessions (the requested laboratory test has been performed and the report has been issued to the requesting physician). After the test has been performed and reported, the insurance company and/or patient has an obligation to pay for medically necessary laboratory tests (items (i) and (ii)). Unlike the pharmacy services model, laboratory services are provided prior to insurance company approval; as a result, the seller’s price to buyer is not known until payment is provided (items (iii) and (iv). Based on historical collections, the Company estimates the expected revenues associated with similar tests and recognizes the revenue when testing results have been provided (v). Revenue from NGDx is recognized upon payment at the time the product(s) is released (shipment delivered using a common carrier), and the control is transferred which is simultaneous to when payment received and accepted. Revenue from product sales of Olaregen’s Excellagen® is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, contractual arrangement and specific known market events and trends. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. Revenue from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements in place typically specify that a percentage of the gross margin associated with the third-parties’ sales that the Company facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties’ sales of such products (iv). Like pharmacy services described above, revenue is recognized when the prescription is dispensed (picked up by the patient or shipped to the patient using common carrier or delivered by the pharmacies own personnel) (v). Provisions for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based on historical and anticipated rates. The Company determines whether it is the principal or agent for its retail pharmacy contract services on a contract by contract basis. In the majority of its contracts, the Company has determined it is the principal due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in changing the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement in the determination of product or service specifications, and (v) having credit risk. The Company’s obligations under its client contracts for which revenues are reported using the gross method are separate and distinct from its obligations to the third-party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Company is contractually required to pay the third-party pharmacies in its retail pharmacy network for products sold, regardless of whether the Company is paid by its clients. The Company’s responsibilities under its client contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to the third-party retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the prescriber prior to dispensing, suggesting generic alternatives where clinically appropriate, and approving the prescription for dispensing. Although the Company does not have credit risk with respect to Retail Co-Payments or inventory risk related to retail network claims, management believes that all of the other applicable indicators of gross revenue reporting are present. For contracts under which the Company acts as an agent, revenue is recognized using the net method.
Adoption of New Accounting Standards	Adoption of New Accounting Standards We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effective dates during the periods reported and in future periods. The Company does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. In February 2016, the FASB issued ASU No. 2016-02, Leases
Recently Issued Accounting Standards	Recently Issued Accounting Standards In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Topic 480, Distinguishing Liabilities from Equity In February 2018, the FASB issued ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement”, which adds disclosure requirements to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. The Company is evaluating the effect that ASU 2018-13 will have on consolidated financial statements.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Oct. 31, 2019
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases as of October 31, 2019: Maturity of Operating Lease Liabilities 2019 $ 64,801 2020 39,879 2021 — 2022 — 2023 — Thereafter $ — Total undiscounted operating lease payments $ 104,680 Less: Imputed interest 6,740 Present value of operating lease liabilities $ 97,940

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Oct. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following components: October 31, July 31, 2019 2019 Raw materials $ 74,444 $ 77,782 Finished goods 652,819 285,226 Total Inventory $ 727,263 $ 363,008

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment, net consisted of the following: October 31, July 31, 2019 2019 Computers and technological assets $ 163,168 $ 163,168 Machinery and equipment 500,576 386,929 Furniture and fixtures 89,123 73,227 Leasehold Improvements 16,596 16,596 769,463 639,920 Less accumulated depreciation (237,575 ) (139,927 ) $ 531,888 $ 499,993

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consist of the following at: October 31, July 31, 2019 2019 In-Process Research & Development $ 8,761,427 $ 8,761,427 Non-compete agreements 1,566,700 1,210,000 Developed software/technology 172,500 131,000 Vendor agreements and other intangibles 775,674 51,274 11,276,301 10,153,701 Less accumulated amortization (473,859 ) (319,432 ) $ 10,802,442 $ 9,834,269
Estimated amortization expense	The remaining estimated amortization expense for the next five years and thereafter is as follows: Year Ending July 31, Amount 2020 $ 570,708 2021 616,744 2022 246,324 2023 94,511 2024 68,491 Thereafter 444,658 $ 2,041,435
Changes in value of goodwill	Changes in the value of goodwill: Balance as of July 31, 2019 $ 38,297,573 Acquisition of MediSource and Pantheon 603,553 Balance as of October 31, 2019 $ 38,901,126

Derivative Liability (Tables)

Derivative Liability (Tables)	3 Months Ended
	Oct. 31, 2019
Notes to Financial Statements
Schedule of Derivative Liabilities at Fair Value	Following table presents the activity for derivative liabilities measured at estimated fair value: Derivative Liability - Convertible Notes Derivative Liability - Warrants Derivative Liability - Downside Protection Total Balance as of July 31, 2019 4,156,196 325,250 3,338,836 7,820,282 Additions during the period 1,021,996 30,353 — 1,052,349 Change in fair value (1,131,157 ) (66,456 ) 3,033,820 1,836,207 Change due to exercise / redemptions (1,875,052 ) (36,432 ) — (1,911,484 ) Balance as of October 31, 2019 $ 2,171,983 $ 252,715 $ 6,372,656 $ 8, 797,354

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Oct. 31, 2019
Share-based Payment Arrangement [Abstract]
Common stock options granted, forfeited or expired and exercised	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Options Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2019 7,988,675 $ 0.84 7.21 $ 15,961,391 Granted 1,003,000 $ 2.09 4.92 — Forfeited or expired (130,000 ) $ 1.11 7.65 — Exercised — — — — Outstanding - October 31, 2019 8,861,675 $ 0.98 6.71 $ 5,859,392
Fair value assumptions used in Black-Scholes option-pricing	The following assumptions were used in the Black-Scholes option-pricing model: October 31, Exercise price $2.01 – 2.09 Time to expiration 5 years Risk-free interest rate 1.51% - 1.59% Estimated volatility 153.4 % Expected dividend — Stock price at valuation date $2.01 – 2.09

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Oct. 31, 2019
Warrants Abstract
Schedule of warrant activities	A summary of the Company’s warrant activities is as follows: Number of Warrants Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2019 15,399,681 $ 2.53 0.40 $ 4,500,000 Issued 62,857 3.50 5.01 — Forfeited (57,143 ) 3.50 — — Outstanding - October 31, 2019 15,405,395 $ 2.52 0.18 $ —

Net Income Per Share (EPS) (Tab

Net Income Per Share (EPS) (Tables)	3 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Computation of diluted EPS	Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. Three Months Ended October 31, 2019 2018 Weighted average number of common shares outstanding - Basic 53,186,407 22,806,777 Potentially dilutive common stock equivalents — 31,892,421 Weighted average number of common and equivalent shares outstanding - Diluted 53,186,407 54,699,198
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table provides weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, for the three months ended October 31, 2019 and 2018, respectively. Three Months Ended October 31, 2019 2018 Series H Convertible Preferred Stock — 25,200,000 Series I Convertible Preferred Stock — 6,636,000 Convertible debt 3,744,548 — Stock options 8,871,675 2,747,850 Warrants 15,405,395 — Total 28,021,618 34,583,850

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Oct. 31, 2019
Components of acquired intangible assets	The components of the acquired intangible assets were as follows: Preliminary Average Estimated Life Tradename / Trademarks $ 103,000 15 IP/Technology 41,500 5 Business Contracts 346,800 15 Customer Base 274,600 10 Non-compete agreement 356,700 3 $ 1,112,600
Supplemental Pro Forma	Unaudited pro forma results of operations for the three months ended October 31, 2019 and 2018 as though the Company acquired MediSource and Pantheon on the first day of each fiscal year are set forth below. Three months Ended October 31, 2019 2018 Revenues $ 721,661 $ 2,141,000 Cost of revenues 133,618 987,409 Gross profit 588,043 1,153,591 Operating expenses 5,136,754 2,629,854 Operating loss (4,548,711 ) (1,476,262 ) Other income (expense) (4,763,836 ) 19,389,944 Net loss $ (9,312,547 ) 17,913,682 Comprehensive net loss $ (9,312,547 ) $ 17,913,682
Medisource
Summary of allocation of preliminary purchase price	The following table summarizes the allocation of the preliminary purchase price as of the MediSource acquisition: Preliminary Cash and cash equivalents $ 13,895 Other current assets 11,864 Property and equipment, net 8,992 Accounts payable and accrued liabilities (31,439 ) Net Tangible Assets $ 3,312 Tradename / Trademarks 47,600 Business Contracts 346,800 Non-Competes 124,600 Total Fair Value of Assets Acquired 522,312 Consideration: Fair value of common stock 479,980 Contingent consideration 409,790 Consideration included in consulting agreement 104,168 Total Purchase Price 993,938 Goodwill $ 471,626
Pantheon [Member]
Summary of allocation of preliminary purchase price	The following table summarizes the allocation of the preliminary purchase price as of the Pantheon acquisition: Preliminary Cash and cash equivalents $ 35,410 Accounts receivable 133,269 Prepaid expenses 3,336 Inventory 266,071 Medical Equipment, net 67,299 Accounts payable (53,242 ) Accrued liabilities (15,573 ) Net Tangible Assets $ 436,570 Tradename / Trademarks 55,400 IP/Technology 41,500 Non-compete agreement 232,100 Customer Base 274,600 Total assets acquired $ 1,040,170 Consideration: Fair value of common stock 671,972 Contingent consideration 354,292 Consideration included in consulting agreement 145,833 Goodwill $ 131,927

Organization of Business and _2

Organization of Business and Going Concern (Details Narrative) - USD ($)	Jan. 07, 2019	Oct. 31, 2019	Jul. 31, 2019	Jan. 18, 2017
Accumulated deficit		$ (427,853,820)	$ (418,727,875)
Working capital deficiency		$ 32,500,000
Secured promissory note Description	On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product. In the first quarter of 2020 the Company acquired increased its ownership of Olaregen to 77%.
Hema Diagnostic Systems, LLC
Majority interest				51.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019
Accounting Policies [Abstract]
Decrease in deferred tax assets	$ 70,000,000		$ 31,876,520
Federal income tax rate	21.00%	35.00%

Loan from Related Parties (Deta

Loan from Related Parties (Details Narrative)	Oct. 31, 2019USD ($)
Outstanding balance	$ 72,612
Regentys
Outstanding balance	19,700
Pantheon [Member]
Accounts receivable	$ 52,912

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)

Dec. 02, 2018

Nov. 27, 2019

Aug. 22, 2017

Dec. 31, 2011

Oct. 31, 2019

Nov. 16, 2012

Sep. 30, 2019

Aug. 31, 2019

Jul. 31, 2019

May 31, 2019

Apr. 30, 2019

Feb. 28, 2019

Jan. 24, 2019

Oct. 26, 2018

Commitments and Contingencies

The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs.

Litigation awards for damages

$ 315,695

Litigation awards, exercisable shares

84,000

Exercise price

$ 2.50

Note amount

$ 2,222,500

$ 1,150,000

$ 446,600

$ 2,000,000

$ 1,060,000

$ 1,500,000

$ 530,000

$ 682,000

Value of the warrants

$ 65,613

Liquidated damages

220,000

Accrued Liquidated damages

285,613

Accrued claim

$ 2,752,235

Alternative Execution Group [Member]

Memorandum of Understanding description

The petition includes a demand of $3,300,360 as the value of the Warrants. The arbitrator did not award the specific amount of $3.3 million, but only liquidated damages in the amount of $220,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees.

Olaregen

Intellectual property acquired

$ 650,000

Damages for Unpaid Invoices

Value of damages sought

$ 429,000

Lawsuit filing date

31-Dec-11

Name of Plaintiff

Vendor

Settlement of litigation

$ 125,000

Interest per annum, failure to pay settlement

3.00%

Fixed cost per annum, failure to pay settlement

$ 25,000

Breach of contract and detinue

Counterclaim proceeding

$ 200,000

Leases (Details)

Leases (Details)	Oct. 31, 2019USD ($)
Leases [Abstract]
2019	$ 64,801
2020	39,879
2021	0
2022	0
2023	0
Thereafter	0
Total undiscounted operating lease payments	104,680
Less: Imputed interest	6,740
Present value of operating lease liabilities	$ 97,940

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended
	Oct. 31, 2019USD ($)
Leases [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	1 year 3 months 19 days
Weighted-average discount rate	9.50%
Operating lease expense	$ 21,508

Inventory (Details)

Inventory (Details) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 74,444	$ 77,782
Finished goods	652,819	285,226
Total Inventory	$ 727,263	$ 363,008

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Property and equipment	$ 769,463	$ 639,920
Less accumulated depreciation	(237,575)	(139,927)
Property and equipment, net	531,888	499,993
Computers and technological assets
Property and equipment	163,168	163,168
Machinery and Equipment [Member]
Property and equipment	500,576	386,929
Furniture and Fixtures [Member]
Property and equipment	89,123	73,227
Leasehold Improvements [Member]
Property and equipment	$ 16,596	$ 16,596

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 48,847	$ 25,664

Goodwill and Intangible Assets_

Goodwill and Intangible Assets: Intangible assets (Details) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Intangible assets gross	$ 11,276,301	$ 10,153,701
Less accumulated amortization	(473,859)	(319,432)
Intangible assets net	10,802,442	9,834,269
In Process Research and Development [Member]
Intangible assets gross	8,761,427	8,761,427
Noncompete Agreements [Member]
Intangible assets gross	1,566,700	1,210,000
Developed Software/Technology [Member]
Intangible assets gross	172,500	131,000
Vendor agreements and other intangibles [Member]
Intangible assets gross	$ 775,674	$ 51,274

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets: Estimated amortization expense (Details)	Oct. 31, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 570,708
2021	616,744
2022	246,324
2023	94,511
2024	68,491
Thereafter	444,658
Total	$ 2,041,435

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets: Changes in value of goodwill (Details)	3 Months Ended
	Oct. 31, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Balance at beginning	$ 38,297,573
Acquisition of MediSource and Pantheon	603,553
Balance at end	$ 38,901,126

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 154,426	$ 646

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended							2 Months Ended	3 Months Ended
	Aug. 31, 2019	Jul. 31, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Jan. 24, 2019	Oct. 26, 2018	Sep. 30, 2019	Oct. 31, 2019	Oct. 31, 2019	Oct. 31, 2018	Dec. 28, 2017
Note amount	$ 1,150,000	$ 446,600	$ 2,000,000	$ 1,060,000	$ 1,500,000	$ 530,000	$ 682,000	$ 2,222,500
Purchase price of note	1,000,000	400,000		1,000,000	1,425,000	505,000	550,000	1,976,745
Investor fee							15,000
Original issue discount	$ 150,000	$ 46,600		$ 60,000	$ 75,000	$ 25,000	$ 147,000	245,755
Effective interest							27.50%					3.00%
Interest rate	10.00%	9.00%	7.00%	10.00%	10.00%	10.00%
Due date			Aug. 1, 2019				Oct. 26, 2019
Number of warrants sold				176,968	102,143	30,285
Payment of Promissory Note										$ 320,000
Common stock issued for conversion debt, Shares										1,164,190
Common stock issued for conversion debt, Value										$ 1,736,900
Derivative liability		$ 206,548						$ 1,052,349
Amortization of debt discount										2,065,835
Debt discount									$ 1,473,842	1,473,842
Notes payable									950,000	950,000
Loss on settlement of debt										(403,214)	$ 0
Regentys
Note amount									349,656	349,656
Accrued interest										39,191
Debt discount									3,719	3,719
Minimum [Member]
Interest rate								9.00%
Maximum [Member]
Interest rate								10.00%
Principal
Common stock issued for conversion debt, Value									$ 110,000	615,000
Notes Payable
Loss on settlement of debt										403,214
Settlement of debt										900,000
Notes Payable | Principal
Common stock issued for conversion debt, Value										$ 350,000

Derivative Liability (Details)

Derivative Liability (Details) - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Derivative liabilities at beginning	$ 7,820,282
Additions during the period	1,052,349
Change in fair value	1,836,208	$ 0
Change due to exercise / redemptions	(1,911,484)
Derivative liabilities at end	8,797,354
Derivative Liability Convertible Notes
Derivative liabilities at beginning	4,156,196
Additions during the period	1,021,996
Change in fair value	(1,131,157)
Change due to exercise / redemptions	(1,875,052)
Derivative liabilities at end	2,171,983
Derivative Liability Warrants
Derivative liabilities at beginning	325,250
Additions during the period	30,353
Change in fair value	(66,456)
Change due to exercise / redemptions	(36,432)
Derivative liabilities at end	252,715
Derivative Liability Downside Protection
Derivative liabilities at beginning	3,338,836
Additions during the period	0
Change in fair value	3,033,820
Change due to exercise / redemptions	0
Derivative liabilities at end	$ 6,372,656

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Sep. 12, 2019	Jan. 07, 2019	Aug. 31, 2019	Oct. 31, 2019	Jul. 31, 2019
Common stock payable, Shares				296,793
Common stock payable, Amount				$ 215,793
Common stock issued				286,377
Common stock issued for conversion debt, Shares				1,164,190
Common stock issued for conversion debt, Value				$ 1,736,900
Cancellation of common stock	20,375,900
Common stock, shares outstanding				44,336,023	62,290,940
Regentys
LOI Terms		Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of October 31, 2019, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.
Olaregen
LOI Terms		Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock. In May 2019, the Company issued 4,000,000 shares of common stock and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. On August 16, 2019, the Company entered into a Share Exchange Agreement to purchase an additional 900,000 shares of common stock in Olaregen from other shareholders of Olaregen in exchange for 1,905,912 shares of Generex common stock and 476,478 shares of Antigen common stock. In September 2019, the Company converted all of the Series A Preferred Stock of Olaregen into common stock of Olaregen.
Common stock, shares outstanding				6,236,390
Preferred stock, shares outstanding				0
Non-controlling interest				1,461,075
Percentage of non-controlling interest				23.43%
Medisource
Common stock issued for acquisition			400,000
Stock Price			$ 2.50
Pantheon [Member]
Common stock issued for acquisition			560,000
Stock Price			$ 2.50

Redeemable Non-Controlling In_2

Redeemable Non-Controlling Interest (Details Narrative) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Notes to Financial Statements
Redeemable Non-Controlling Int	$ 4,073,898	$ 4,073,898

Stock-Based Compensation - Comm

Stock-Based Compensation - Common stock options granted, forfeited or expired and exercised (Details) - USD ($)	3 Months Ended	12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Options Outstanding, Beginning	7,988,675
Options Granted	1,003,000
Options Forfeited or expired	(130,000)
Options Exercised	0
Options Outstanding, End	8,861,675	7,988,675
Weighted Average Exercise Price per Share, Beginning	$ 0.84
Weighted Average Exercise Price per Share, Granted	2.09
Weighted Average Exercise Price per Share, Forfeited or expired	1.11
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, End	$ 0.98	$ 0.84
Weighted Average Remaining Life Options Outstanding (Years)	6 years 8 months 16 days	7 years 2 months 16 days
Weighted Average Remaining Life Options Granted	4 years 11 months 1 day
Weighted Average Remaining Life Options Forfeited or expired	7 years 7 months 24 days
Aggregate Intrinsic Value Options, Outstanding Beginning	$ 15,961,391
Aggregate Intrinsic Value Options Granted
Aggregate Intrinsic Value Options, Outstanding Ending	$ 5,859,392	$ 15,961,391

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair value assumptions used in Black-Scholes option-pricing (Details)	3 Months Ended
	Oct. 31, 2019$ / shares
Time to expiration	5 years
Estimated volatility	153.40%
Expected dividend	0.00%
Minimum [Member]
Exercise price	$ 2.01
Risk-free interest rate	1.51%
Stock price at period end date	$ 2.01
Maximum [Member]
Exercise price	$ 2.09
Risk-free interest rate	1.59%
Stock price at period end date	$ 2.09

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Market value	$ 1.53
Compensation expense	$ 787,458	$ 103,194
Stock Options
Compensation expense	787,458
Unrecognized compensation costs	$ 4,256,191
Unrecognized compensation period	2 years 8 months 2 days
Stock Option Plan 2006
Common stock reserved for future issuance	2,835,000
Common stock reserved for future awards	2,823,450
Options vested	3,540,675
Stock Option Plan 2017
Common stock reserved for future issuance	240,000,000
Common stock reserved for future awards	231,149,875
Stock Option Plan 2019
Common stock reserved for future issuance	1,200,000

Warrants (Details)

Warrants (Details)	3 Months Ended
	Oct. 31, 2019USD ($)$ / sharesshares
Warrants Abstract
Number of Warrants Outstanding at beginning	15,399,681
Number of Warrants issued	62,857
Number of Warrants Forfeited	(57,143)
Number of Warrants Outstanding at end	15,405,395
Weighted Average Exercise Price per Share Outstanding at beginning | $ / shares	$ 2.53
Weighted Average Exercise Price per Share issued	3.50
Weighted Average Exercise Price per Share Forfeited | $ / shares	$ 3.50
Weighted Average Exercise Price per Share Outstanding at end | $ / shares	$ 2.52
Weighted Average Remaining Life of Warrants Outstanding at beginning (Years)	4 months 24 days
Weighted Average Remaining Life of Warrants issued (Years)	5 years 4 days
Weighted Average Remaining Life of Warrants Outstanding at end (Years)	2 months 5 days
Aggregate Intrinsic Value Warrants Outstanding at beginning | $	$ 4,500,000
Aggregate Intrinsic Value Warrants issued | $	0
Aggregate Intrinsic Value Warrants Forfeited | $	0
Aggregate Intrinsic Value Warrants Outstanding at end | $	$ 0

Warrants (Details Narrative)

Warrants (Details Narrative)	3 Months Ended
	Oct. 31, 2019shares
Number of Warrants issued	62,857
Number of warrants forfeited	57,143
Investors
Number of Warrants issued	62,857
AEXG
Number of Warrants issued	84,000

Net Income Per Share (_EPS_) -

Net Income Per Share (“EPS”) - Computation of diluted EPS (Details) - shares	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Accounting Policies [Abstract]
Weighted average number of common shares outstanding - Basic	53,186,407	22,806,777
Potentially dilutive common stock equivalents		31,892,421
Weighted average number of common and equivalent shares outstanding-Diluted	53,186,407	54,699,198

Net Income Per Share (_EPS_) _2

Net Income Per Share (“EPS”) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Total	28,021,618	34,583,850
Series H Convertible Preferred Stock
Total	0	25,200,000
Series I Convertible Preferred Stock
Total	0	6,636,000
Convertible Debt
Total	3,744,548	0
Stock options
Total	8,871,675	2,747,850
Warrants
Total	15,405,395	0

Acquisitions - Fair Value of th

Acquisitions - Fair Value of the Medisource Acquisition (Details) - USD ($)	Oct. 31, 2019	Aug. 02, 2019	Jul. 31, 2019	Oct. 31, 2018	Jul. 31, 2018
Cash and cash equivalents	$ 540,254		$ 298,485	$ 2,363,740	$ 1,046,365
Other current assets	451,344		275,731
Property and equipment, net	531,888		499,993
Accounts payable and accrued liabilities	(22,447,533)		(19,055,822)
Consideration:
Goodwill	$ 38,901,126		$ 38,297,573
Medisource
Cash and cash equivalents		$ 13,895
Other current assets		11,864
Property and equipment, net		8,992
Accounts payable and accrued liabilities		(31,439)
Net Tangible Assets		3,312
Tradename / Trademarks		47,600
Business Contracts		346,800
Non-Competes		124,600
Total Fair Value of Assets Acquired		522,312
Consideration:
Fair value of common stock		479,980
Contingent consideration		409,790
Consideration included in consulting agreement		104,168
Total Purchase Price		993,938
Goodwill		$ 471,626

Acquisitions - Fair Value of _2

Acquisitions - Fair Value of the Pantheon Acquisition (Details) - USD ($)	Oct. 31, 2019	Aug. 02, 2019	Jul. 31, 2019	Oct. 31, 2018	Jul. 31, 2018
Cash and cash equivalents	$ 540,254		$ 298,485	$ 2,363,740	$ 1,046,365
Inventory	727,263		363,008
Medical Equipment, net	531,888		499,993
Consideration:
Goodwill	$ 38,901,126		$ 38,297,573
Pantheon [Member]
Cash and cash equivalents		$ 35,410
Accounts receivable		133,269
Prepaid Expenses		3,336
Inventory		266,071
Medical Equipment, net		67,299
Accounts payable		(53,242)
Accrued liabilities		(15,573)
Net Tangible Assets		436,570
Tradename / Trademarks		55,400
IP/Technology		41,500
Non-compete agreement		232,100
Customer Base		274,600
Total assets acquired		1,040,170
Consideration:
Fair value of common stock		671,972
Contingent consideration		354,292
Consideration included in consulting agreement		145,833
Goodwill		$ 131,927

Acquisitions - Estimated amorti

Acquisitions - Estimated amortization expense (Details) - Preliminary Fair Value	Aug. 02, 2019USD ($)
Total	$ 1,112,600
Tradename / Trademarks [Member]
Total	$ 103,000
Average Estimated Life	15 years
IP/Technology [Member]
Total	$ 41,500
Average Estimated Life	5 years
Business Contracts [Member]
Total	$ 346,800
Average Estimated Life	15 years
Customer Base [Member]
Total	$ 274,600
Average Estimated Life	10 years
Noncompete Agreements [Member]
Total	$ 356,700
Average Estimated Life	3 years

Acquisitions - Unaudited Supple

Acquisitions - Unaudited Supplemental Pro Forma Data (Details) - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Business Combinations [Abstract]
Revenues	$ 721,661	$ 2,141,000
Cost of revenues	133,618	987,409
Gross profit	588,043	1,153,591
Operating expenses	5,136,754	2,629,854
Operating loss	(4,548,711)	(1,476,262)
Other income (expense)	(4,763,836)	19,389,944
Net loss	(9,312,547)	17,913,682
Comprehensive net loss	$ (9,312,547)	$ 17,913,682

Acquisitions (Details Narrative

Acquisitions (Details Narrative)	Aug. 02, 2019
Business Combinations [Abstract]
Business combination description	Under the APAs:

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019
Pre-tax gain or (loss) arising from domestic operations	$ (9,179,902)	$ (11,006,793)
Pre-tax (losses) arising from foreign operations	(10,963)	$ (326,461)
Decrease in deferred tax assets	70,000,000		$ 31,876,520
Generex Pharmaceuticals
NOL carryforwards	214,000,000
Antigen Express
NOL carryforwards	36,200,000
Regentys
NOL carryforwards	6,100,000
Olaregen
NOL carryforwards	$ 1,300,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 12, 2019	Dec. 12, 2019	Dec. 05, 2019	Dec. 05, 2019	Nov. 14, 2019	Nov. 12, 2019	Nov. 12, 2019	Nov. 29, 2019	Nov. 27, 2019	Nov. 27, 2019	Nov. 25, 2019	Nov. 24, 2019	Nov. 22, 2019	Nov. 21, 2019	Nov. 21, 2019	Nov. 18, 2019	Aug. 31, 2019	Jul. 31, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Jan. 24, 2019	Oct. 31, 2019	Oct. 31, 2019	Sep. 30, 2019	Oct. 26, 2018
Common stock issued for conversion debt, Shares																								1,164,190
Common stock issued for conversion debt, Value																								$ 1,736,900
Note amount																	$ 1,150,000	$ 446,600	$ 2,000,000	$ 1,060,000	$ 1,500,000	$ 530,000			$ 2,222,500	$ 682,000
Common stock issued																		62,290,940					44,336,023	44,336,023
Interest rate																	10.00%	9.00%	7.00%	10.00%	10.00%	10.00%
Principal
Common stock issued for conversion debt, Value																							$ 110,000	$ 615,000
Subsequent Event [Member]
Common stock issued for conversion debt, Shares	128,561	181,007	180,682	192,494	80,110	115,344	128,561	79,214	202,635	251,859				134,865	169,543
Subsequent Event [Member] | ALTuCELL [Member]
Common stock description													ALTuCELL Stock, Generex will issue to ALTuCELL 1,600,000 shares of Generex common stock with a down round provision and price floor of $1.25 per share. The Company will also pay $2.5 million in cash of which $112,000 has already been paid. In addition to stock and cash at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCell upon ALTuCell’s attainment of certain milestones.
Subsequent Event [Member] | Investors
Common stock description											Company entered an Equity Purchase Agreement with an investor to purchase up to $40,00,000 of the Company’s stock at 92% of the market price for the period of five (5) consecutive trading days immediately subject to a put notice on such date on which the Purchase Price is calculated in accordance with the terms and conditions of this Agreement and 1,228,501 shares of common stock (“Commitment Shares”) upon signing were issued to an investor.
Subsequent Event [Member] | Olaregen
Stock Purchase Agreement description												Company amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November 30, 2019, in connection with the purchase of Olaregen capital stock. Effective November 24, 2019, the deadline has been extended to January 31, 2020.
Subsequent Event [Member] | Regentys
Stock Purchase Agreement description											Company amended the Stock Purchase Agreement with Regentys originally on January 7, 2019. Effective November 25, 2019, the remaining three payments of $2,039,001, $2,000,000, and $3,000,000 are all payable on or before December 30, 2019.
Subsequent Event [Member] | Equity Purchase Agreement | Investors
Note amount			$ 2,200,000	$ 2,200,000
Common stock issued			100,000	100,000
Subsequent Event [Member] | Securities Purchase Agreement | Investors
Note amount																$ 275,000
Interest rate																10.00%
Subsequent Event [Member] | Principal
Common stock issued for conversion debt, Value	$ 50,000	$ 75,000	$ 70,000	$ 75,000	$ 50,000	$ 80,000	$ 50,000	$ 50,000	$ 100,000	$ 125,000				$ 80,000	$ 100,000
Subsequent Event [Member] | Interest
Common stock issued for conversion debt, Value	$ 3,096	$ 4,756	$ 4,621	$ 4,500	$ 2,712	$ 4,778	$ 3,096		$ 6,384	$ 7,226				$ 4,493
Subsequent Event [Member] | Accrued Interest
Common stock issued for conversion debt, Value															$ 6,219